Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Recently, some experts have raised concerns that novel weight loss drugs – known as glucagon-like peptide-1 (GLP-1) receptor ...

A new research study appears to be linking Ozempic to risks of hearth muscle loss at a point when manufacturers are being hit ...

Trendy weight-loss drugs making headlines for shrinking waistlines may also be shrinking the human heart and other muscles, ...

As populations age, the prevalence of sarcopenia—a progressive loss of muscle mass and function—has become an increasingly ...